Lantern Pharma (LTRN) Stock: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$1.91
0.03 (1.87%)
▲
5d:
-7.97%
30d:
-31.47%
90d:
-46.94%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LTRN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LTRN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $1.91, which is considered oversold relative to its 30-day fair value range of $2.12 to $2.74.
Technical Outlook: Technically, LTRN is showing sideways momentum. Immediate support is located at $1.81, while resistance sits at $2.40.
Market Sentiment: LTRN scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.50 (+818.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LTRN is showing sideways momentum. Immediate support is located at $1.81, while resistance sits at $2.40.
Market Sentiment: LTRN scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.50 (+818.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.12 -
$2.74
Company Quality Score
47/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 818.6% below Wall St target ($17.50)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.12 -
$2.74
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.49
(25.7%)
Support & Resistance Levels
Support Level
$1.81
Resistance Level
$2.40
Current Trend
Sideways
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.94
Wall Street Target
$17.50
(+818.6%)
Share & Embed Analysis
Last updated: September 05, 2026 5:03 PM ET
Data refreshes hourly during market hours. Next update: 6:03 PM
Data refreshes hourly during market hours. Next update: 6:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 55 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 56 HOLD |
